NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
Keyword(s):
Phase Ii
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. 11053-11053
◽